Podium to Practice: EHA 2026 – Multiple Myeloma: IBERDOMIDE-BASED QUADRUPLET in NDMM

Studies / Trials Discussed

S199 – SAFETY AND EFFICACY OF IBERDOMIDE-BASED QUADRUPLET FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: THE IDEAL PHASE I/II TRIAL RESULTS

Explore more from your favourite experts – click their name to access their entire library of content.

Studies/trials discussed:

S199 – SAFETY AND EFFICACY OF IBERDOMIDE-BASED QUADRUPLET FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: THE IDEAL PHASE I/II TRIAL RESULTS

Abstract of the paper or summary description of the presentation:

LB5008 – TECLISTAMAB IMPROVES DEPTH OF RESPONSE AND PFS VERSUS LENALIDOMIDE-DEXAMETHASONE IN HIGH-RISK SMOLDERING MULTIPLE MYELOMA: RESULTS FROM THE PHASE 2 IMMUNOPRISM TRIAL